Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

People on testosterone replacement therapy (TRT) with aggressive androgenetic alopecia (AGA) discuss using Dutasteride or Finasteride, sometimes combined with topical treatments like RU58841 or CB-03-01 (Breezula), to prevent hair loss. Concerns about side effects and costs of certain treatments are mentioned, with one individual sharing their experience of slowed hair loss using Finasteride alone.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

Topical 2-deoxy-D-ribose (2dDR) regrows hair in mice almost as well as 2% Minoxidil. However, 2dDR may contribute to oxidative stress and hair loss due to the formation of advanced glycation end products (AGEs).

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

OP used 1mg finasteride for 4 years, then had a hair transplant, and for the past 6 months has been using 0.5mg dutasteride and 2.5mg oral minoxidil twice daily. The treatments resulted in significant hair density and thickness improvement.

A user is considering switching from finasteride to dutasteride due to unsatisfactory results and is concerned about experiencing another shedding phase. Another user recently made the switch and will update on their experience.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.

A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.

The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.

A 23-year-old started using 0.5mg Dutasteride and 2.5mg Minoxidil daily for hair loss and is considering adding RU58841 or GHK-cu. Users suggest waiting a few months before adding anything and mention Koshine's kx-826 as a potentially better alternative to RU58841.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

Glycine supplementation may increase 5-alpha reductase activity, potentially affecting hair loss. Users discuss its impact on hair fall and its role in the body.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

Finasteride is prescribed at 1mg because it is FDA-approved and proven effective, despite evidence that 0.2mg may similarly reduce DHT. The 1mg dose is more effective for hair growth, and lower doses are less available.

Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.

The user is excited about an upcoming update for GT20029, expected in March. They express frustration with the negativity on Reddit.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.

The user experienced hair improvement using 1mg finasteride daily for six months, managing seborrheic dermatitis with rosemary and eucalyptus oil. They are considering switching to dutasteride for potentially better results.

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.